Method for the production of propellant gas-free aerosols from aqueous medicament preparations

Abstract

The present invention relates to pharmaceutical preparations in the form of aqueous solutions for the production of propellant-free aerosols.

1 . An aqueous pharmaceutical preparation in the form of a solution for the production of propellant-free aerosols for inhalation comprising a pharmacologically active ingredient, characterised in that the pharmaceutical preparation contains a complexing agent.  
     
     
         2 . A pharmaceutical preparation according to  claim 1 , characterised in that the active ingredient is intended for application by inhalation, especially for the treatment of respiratory passage diseases.  
     
     
         3 . A pharmaceutical preparation according to  claim 2 , characterised in that the active ingredient is selected from the group betamimetics, anticholinergics, antiallergics and/or antihistamines.  
     
     
         4 . A pharmaceutical preparation according to claims  1 ,  2  or  3 , characterised in that the active ingredient is selected from the group 
 Fenotrol, Ipatropium bromide, Berotec, Atrovent, Berodual, Salbutamol, Combivent, Ba 679 Br, BEA 2108 Br, Oxivent.  
 
     
     
         5 . A pharmaceutical preparation according to any one of  claims 1  to  4 , characterised in that the complexing agent is nitrilotriacetic acid, citric acid, ascorbic acid or salts thereof.  
     
     
         6 . A pharmaceutical preparation according to any one of  claims 1  to  4 , characterised in that the complexing agent is EDTA or a salt thereof.  
     
     
         7 . A pharmaceutical preparation according to any one of  claims 1  to  6 , characterised in that the concentration of the complexing agent is between 10 and 100 mg/100 ml solution.  
     
     
         8 . A pharmaceutical preparation according to  claim 7  characterised in that the concentration of the complex former is between 25 and 75 mg/100 ml solution.  
     
     
         9 . A pharmaceutical preparation according to one of  claims 1  to  8 , characterised in that the adjuvant is a preservative.  
     
     
         10 . A pharmaceutical preparation according to  claim 9 , characterised in that the preservative is Benzalkonium chloride.  
     
     
         11 . A pharmaceutical preparation according to any one of the previous claims, characterised in that the pharmaceutical preparation contains up to 70% (by volume) ethanol.  
     
     
         12 . A pharmaceutical preparation according to one of the previous claims, characterised in that it contains the active ingredient in a concentration of 0.001 to 2 g/100 ml solution.  
     
     
         13 . A pharmaceutical preparation according to any one of the previous claims, characterised in that it contains pharmacologically acceptable adjuvant and flavouring substances.  
     
     
         14 . The use of aqueous pharmaceutical preparations in the production of propellant-free aerosols for inhalation, characterised in that the pharmaceutical preparations contain a complexing agent.  
     
     
         15 . The use according to  claim 14 , characterised in that the active ingredient is selected from the group Betamimetics, Anticholinergics, Antiallergics and/or antihistamines.  
     
     
         16 . The use according to  claim 14  or  15 , characterised in that the active ingredient is selected from the group 
 Fenotrol, Ipatropium bromide, Berotec, Atrovent, Berodual, Salbutamol, Combivent, Ba 679 Br, BEA 2108 Br, Oxivent.  
 
     
     
         17 . The use according to any one of  claims 14  to  16 , characterised in that the complexing agent is nitriloacetic acid, citric acid, ascorbic acid or a salt thereof.  
     
     
         18 . The use according to any one of  claims 14  to  16 , characterised in that the complexing agent is EDTA or a salt thereof.  
     
     
         19 . The use according to  claim 18 , characterised in that the concentration of the complexing agent is between 25 and 75 mg.  
     
     
         20 . The use according to any one of  claims 14  to  19 , characterised in that the pharmaceutical preparation contains up to 70% (by volume) ethanol.  
     
     
         21 . The use according to any one of  claims 14  to  20 , characterised in that the pharmaceutical preparation contains active ingredient in a concentration of 0.001 to 2 g/100 ml solution.